AAV gene therapy vectors [7] [8] [9] . However, most of these findings were obtained in mice with tumor-prone or disease-associated genotypes, and they stand in contrast to the excellent safety record of AAV vectors in large animal models as well as in numerous preclinical studies in mice that have supported moving them forward in human clinical trials. A notable exception is the observation that AAV vector integration into the Rian locus in normal newborn mice causes HCC, with increased expression of a set of surrounding microRNAs and small nucleolar RNAs (snoRNAs) whose counterparts are also overexpressed in some human HCCs 10 . Interestingly, these integrations are centered around one specific microRNA gene in the Rian locus (Mir341) that is not conserved in humans 11 , which could explain the lack of wild-type AAV insertions found in the syntenic human MEG8 locus by Nault et al. 4 (Fig. 1) .
Does the finding that wild-type AAV integration can lead to human HCC shed light on the risks of gene therapy? In one sense, this study is reassuring because the critical 3′ capsid gene fragment present in wild-type AAV insertions is absent from AAV vectors. However, a larger concern is the novel observation that an enhancer-promoter element packaged in an AAV virion can integrate and activate a proto-oncogene in human hepatocytes, as most AAV vectors by necessity include a strong loci, with 21% of matched non-tumor liver specimens containing nonclonal AAV sequences. The HCCs with AAV insertions were enriched in patients without underlying cirrhosis, suggesting that AAV-induced inflammation was not a major contributor to oncogenicity (unlike in HBV-associated HCC). More than 50% of the population of the United States is thought to be infected with AAV, but no chronic hepatitis seems to have developed as a result. The absence of chronic liver injury in AAV infections may explain why the relative risk of developing HCC is lower than with HBV. Nonetheless, these results clearly indicate that insertional mutagenesis by AAV can cause malignant transformation in the liver, apparently without additional insults. This is remarkable given that AAV is generally considered a respiratory virus and requires a helper virus, such as adenovirus, for productive infection. The frequent presence of viral sequences in liver specimens suggests that the virus can also enter the bloodstream and infect internal organs at high levels. It remains to be seen whether similar oncogenic insertions occur in other types of human tumors.
Gene therapy and hepatocellular carcinoma
In mice, HCC can be induced by chromosomal integration of transposons, lentiviral vectors or AAV and cancer Hepatocellular carcinoma (HCC) is one of the few cancers showing an increasing frequency of incidence in the developed world, with most cases occurring in the context of liver cirrhosis and chronic inflammation and frequently in association with hepatitis B virus (HBV) infection 1 . Several proto-oncogenes have been found to be overexpressed in human HCC and are thought to be causally related to cancer development. A subset of these genes, including TERT (telomerase reverse transcriptase), CCNE1 (cyclin E1) and KMT2B (lysine-specific methyltransferase 2B), are associated with HBV insertions 2 , with TERT activation being the most frequent genetic event in all HCCs and presumably an early event in the ontogeny 3 . In this issue of Nature Genetics, Jessica Zucman-Rossi and colleagues add to this story by sequencing human HCC samples and finding clonal integrations of sequences derived from wild-type AAV2 at several known HCC driver genes 4 . In vitro modeling demonstrated that these insertions increased the expression of the protooncogenes and that the partial AAV sequences could act as both promoters and enhancers in hepatocytes (Fig. 1) . These data strongly suggest that the AAV integrations actually caused the tumors, similarly to the scenario with HBV integrations.
The results are surprising in several ways, especially because AAV has long been considered a nonpathogenic virus that even has antioncogenic properties 5 . Most of the insertions included a 3′ portion of the AAV2 capsid gene and the 3′ inverted terminal repeat (ITR), which was previously shown to have promoter properties 6 and presumably also contains an enhancer element, as implied by the reverse orientation of some of the insertions. Approximately 6% of the HCCs studied contained clonal AAV insertions at proto-oncogene adeno-associated virus finds its disease enhancer-promoter that is active in the target tissue. In liver-directed gene therapy, integration in as few as 0.1% of hepatocytes would still result in tens of millions of integration events. Consequently, it is likely that some patients will have vector sequences inserted at protooncogene loci. The tumorigenic impact of these insertions is difficult to predict because multiple oncogenic hits may be required for transformation. Even so, it is hard to imagine an exposure to wild-type AAV that is equivalent to the intravenous delivery of >10 13 vector particles that a patient undergoing gene therapy typically might receive, and we now know that, in some cases, exposure to wildtype AAV might be enough to cause a tumor. Moving forward, there are several steps that gene therapists can take to improve the safety of AAV vectors. Careful design of enhancer and promoter elements may minimize the risks of insertional mutagenesis, as demonstrated for integration in the mouse Rian locus 11 . Eventually, the field may adopt promoterless vectors that integrate site specifically, as suggested by the recent demonstration of clotting Factor IX expression from an albumin locus knock-in vector 12 . When targeting tissues other than liver, one should choose vector serotypes with reduced liver tropism and enhancer and promoter elements that are not active in hepatocytes. Chronic hepatic inflammation and cirrhosis are clear contributors to HCC evolution, and patients with such conditions might not be suitable candidates for liver-directed gene therapy. Notably, obesity is a frequent cause of chronic hepatitis 13 and thus could also be a risk factor for AAV-mediated oncogenesis. Similarly, AAV integrations occur more frequently in dividing cells 14 , so the risk of tumor formation could be higher in any setting with hepatocyte proliferation, especially in young children with growing livers. Finally, there should be renewed efforts to eliminate even low levels of contaminating replication-competent AAV from clinicalgrade vector stocks, as these particles could deliver the oncogenic capsid gene element. Close follow-ups of patients treated with AAV vectors will shed light on some of these issues, and renewed research into the potential oncogenicity of AAV vectors is now more important than ever. of the 4 Hox clusters and 66 other PRC1 target genes involved in transcriptional regulatory pathways. Five additional smaller contact networks containing RING1B-bound genes were also detected, showing that a large number of PRC1 target genes cluster in three-dimensional space within the nucleus. Finally, in agreement with previous work 8, 11 , a network involving genes bound by pluripotency factors was also detected, although it was weaker and segregated from the PRC1 target gene networks.
PRC1 enters the stage
To determine whether PRC1 components might have a causal role in the formation of gene networks, Schoenfelder et al. 10 tested the effect of knocking out either RING1A only or both RING1A and RING1B in mouse ESCs. Whereas the loss of RING1A weakened the PRC1 network contacts, double knockout disrupted the Hox gene network, concomitant with a massive derepression of Hox genes. Intriguingly, genes that were linearly close to the formation of two main complexes 5 , PRC1 and PRC2. In addition to silencing their targets by binding to target gene transcription start sites, Polycomb components have been shown to form nuclear foci where target genes associate to stabilize gene silencing in Drosophila melanogaster 6, 7 . Similar networks have also been found in mammals, and the PRC2 subunit EED was shown to contribute to the maintenance of these networks in mouse ESCs 8, 9 . However, the function of PRC1 components in regulating the nuclear organization of their target genes remained to be investigated.
Three-dimensional gene networks
In their new study 10 , Sarah Elderkin and colleagues analyzed the role of chromosome folding in ESC maintenance by using a method called promoter capture Hi-C (ref.
2) and a dedicated data analysis pipeline. This approach showed that genes bound by the PRC1 component RING1B establish contact networks (Fig. 1, top) , the strongest of which include genes Our understanding of gene regulation has advanced greatly in recent years thanks to the extensive use of high-throughput technologies such as Hi-C 1 and its derivatives 2 . In combination with microscopy analysis and genome engineering, these approaches have shown that chromatin forms large domains spanning hundreds of kilobases in which frequent interactions occur between regulatory elements and gene promoters. Long-range interactions within the same chromosome or between different chromosomes further contribute to establishing a multilayered hierarchical organization that orchestrates genome function 3 . Whereas activation of transcription depends on transcriptional inducers (such as the pluripotency transcription factors in embryonic stem cells (ESCs)) 4 , Polycomb proteins maintain cell fates by repressing hundreds of genes through PRC1 proteins orchestrate three-dimensional genome architecture
Giacomo Cavalli
The three-dimensional organization of the genome has an important role in orchestrating gene expression, but its regulation is poorly understood. now, a new study uncovers a major role for Polycomb components of the PRC1 complex in organizing physical networks of genes that are co-repressed to maintain pluripotency.
